The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis.

ABSTRACT:

Introduction

Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30-50% of patients, and markedly decreases their quality of life. In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) published the revised guidelines for the management and treatment of steroid-induced osteoporosis, providing the treatment criteria based on scores of risk factors, including previous fractures, age, GC doses, and bone mineral density, for patients aged ≥18 years who are receiving GC therapy or scheduled to receive GC therapy for ≥3 months.

Materials and methods

The Committee on the revision of the guidelines for the management and tre

SUBMITTER: Tanaka Y 

PROVIDER: S-EPMC10982086 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature